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Abstract
The cell wall of M. tuberculosis is central to its success as a pathogen. Mycolic acids are key components of this cell wall. The
genes involved in joining the a and mero mycolates are located in a cluster, beginning with Rv3799c and extending at least
until Rv3804c. The role of each enzyme encoded by these five genes is fairly well understood, except for Rv3802c. Rv3802 is
one of seven putative cutinases encoded by the genome of M. tuberculosis. In phytopathogens, cutinases hydrolyze the
waxy layer of plants, cutin. In a strictly mammalian pathogen, such as M. tuberculosis, it is likely that these proteins perform a
different function. Of the seven, we chose to focus on Rv3802c because of its location in a mycolic acid synthesis gene
cluster, its putative essentiality, its ubiquitous presence in actinomycetes, and its conservation in the minimal genome of
Mycobacterium leprae. We expressed Rv3802 in Escherichia coli and purified the enzymatically active form. We probed its
activities and inhibitors characterizing those relevant to its possible role in mycolic acid biosynthesis. In addition to its
reported phospholipase A activity, Rv3802 has significant thioesterase activity, and it is inhibited by tetrahydrolipstatin
(THL). THL is a described anti-tuberculous compound with an unknown mechanism, but it reportedly targets cell wall
synthesis. Taken together, these data circumstantially support a role for Rv3802 in mycolic acid synthesis and, as the cell wall
is integral to M. tuberculosis pathogenesis, identification of a novel cell wall enzyme and its inhibition has therapeutic and
diagnostic implications.
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Introduction
M. tuberculosis infects one third of the world, makes over 8
million ill each year, and kills 1.8 million, 450,000 of whom are
children [1]. Though one of the oldest known human pathogens,
our ability to combat spread of this disease remains insufficient
and the global health burden of tuberculosis is increasing [2]. Key
to the success of the tubercule bacillis is its uniquely complex lipid
rich cell wall, and cell wall synthesis pathways are current target
areas for drug development [3–6]. The cell wall of mycobacteria is
considered a bilayer, and the lipids integral to the bilayer are the
myolic acids. Just exterior to the cell membrane lies the mycolyl-
arabinogalactan-peptidoglycan complex (mAGP). This complex
forms the stable scaffolding for the outer component of surface-
exposed lipids and glycolipids, such as trehalose monomycolate
(TMM) and dimycolate (TDM). The mycolic acids of these
glycolipids are noncovalently intercolated with the mAGP.
Mycolic acid containing lipids are not only essential for the
survival of M. tuberculosis, they contribute to pathogenesis through a
variety of mechanisms from cell signaling and host evasion to
granuloma formation. The genes involved in joining the mero and
a mycolate into a mature mycolic acid and transferring it to
trehalose or arabinogalactan are located in a gene cluster from
Rv3799c to at least Rv3804c (Figure 1). The role of each enzyme
encoded by these five genes is fairly well understood, except for the
product of Rv3802c, though these five genes do not account for all
the necessary steps in the pathway [7]. A summary is presented in
Figure 2. In brief, FadD32 (fatty acid dehydrogenase, Rv3801c)
and AccD4 (Rv3799c), along with the other acyl-CoA carboxylases,
AccA3 and AccD5, participate in deriving meroacyl-AMP (from
FAS-II) and 2-carboxyl-C26-S-CoA (from FAS-I), respectively.
These are attached via thioester bonds to phosphopentathienes on
the acyl carrier domains of Pks13 (polyketide synthase, Rv3800c), a
multidomain protein which, via Claisen condensation, creates a
mature mycolic acid. A reduction step is needed and one enzyme
so far, CmrA, has been identified for this role [8]. The deposition
and export of the mycolates is less well understood. A mature
mycolic acid is eventually transferred either to arabinogalactan (to
form mAGP) in part by the Ag85 proteins, or to an a,a-trehalose-
6-phosphate (T6P, leading to TMM) by an unknown mycolyl-
transferase [9]. A phospholipid carrier, 6-0-mycolyl-a-D-manno-
pyranosyl-1-monophosphoheptaprenol (Myc-PL), is reported to be
involved in Mycobacterium smegmatis[10]. For TDM formation, a
second mycolic acid is added to TMM by the antigen 85 complex
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we investigated the possible contributions of the Rv3802c gene
product to the mycolic acid synthesis pathway. Our data
demonstrate that the products encoded by Rv3802c and the non-
orthologous but homologue MSMEG_1403 possess both phospho-
lipase A (PLA) activity and thioesterase activity. These activities
are consistent with a role in mycolic acid biosynthesis as this
pathway involves multiple ester and thioester bonds. In addition,
the Rv3802c gene product, but not that of the distant homologue
MSMEG_1403 in M. smegmatis, is inhibited by the known human
fatty acid synthase thioesterase (FASTE) domain inhibitor, THL.
THL has been demonstrated to decrease mycolic acid synthesis,
leading to defects in the mycobacterial cell wall, though the targets
of its antimycobacterial action were unknown. Though these lines
of evidence are circumstantial, taken together with the genetic
data, these findings support a role for Rv3802 in mycobacterial
mycolic acid synthesis.
Results
Genome comparisons of the Rv3802c Locus
We analyzed a 30-kb chromosomal region surrounding Rv3802c
in M. tuberculosis H37Rv and compared it to that of other
mycobacteria and corynebacteria. Rv3802c is located in a mycolic
acid synthesis gene cluster from Rv3799c to 3804c, which encode
AccD4, Pks13, FadD32, Rv3802, Ag85D and Ag85A, respectively
(Figure 1). The cluster is conserved in all mycobacteria,
corynebacteria, nocardia, and rhodococci with available annotated
databases, indicative of functionality common to actinomycetes. Of
the seven cutinases present in M. tuberculosis, Rv3802c is the only one
reported to be essential, and is the only one conserved in M. leprae,
which is considered a minimal genome [12,13]. Essentiality was
determined with Himar-1-based mutagenesis experiments in M.
tuberculosis and Mycobacterium bovis BCG, and Rv3802c had an
insertion/genomic probe ratio of 0.08 (cut-off for essentiality
experimentally set below 0.2) [12]. However, this is still a screen
and the essential nature of this gene needs to be confirmed with
deletion/complementation studies. The three upstream genes
encoding the AccD4, Pks13 and FadD32 proteins have similar
insertion/genomic probe ratios (0.02–0.16) and were confirmed to
be essential in M. tuberculosis and M. smegmatis [14,15]. The amino
acid sequence of Rv3802 is highly similar to that its orthologs in
other mycobacteria (76–100%, Figure 3) and is 60% similar to the
ortholog in C. glutamicum; it shares only 0–40% similarity with the
other annotated cutinases in M. tuberculosis. Rv3802 is a 337 amino
acid protein with a predicted secretion signal and an altered, but
recognizable, cutinase motif [16]. The motif contains the classic S,
D, H catalytic triad, though in Rv3802 and orthologs the probable
catalytic H is 30 amino acids from the D rather than the 12
described in the classic motif[16]. This motif places Rv3802 and
the other cutinases in the a/b-hydrolase fold family, in company
with known mycolyltransferases (Ag85 complex), known PLAs and
known thioesterases. Like all a/b-hydrolase fold enzymes, the
predicted structure has an oxyanion hole, which provides a
positively charged hole to stabilize the transient oxyanions formed
during acylation and deacylation, and an acyl binding pocket lined
with hydrophobic residues [17,18]. Rv3802 is predicted to be a
membrane protein, though it is unclear if it is on the cytosolic or
extracytosolic side[19]. It has only one predicted membrane
spanning helix located within the putative secretion signal; the
GRAVY value with and without the secretion signal are 20.15 and
20.29, respectively, implying moderate solubility, though indeed
experimentally it has been found in the membrane fraction [20,21].
Expression and purification of recombinant proteins M.
tuberculosis Rv3802, its mutants, and M. smegmatis
mc
2155 MSMEG_1403 in E. coli
The genes Rv3802c and MSMEG_1403 were PCR-amplified
from their respective genomes without their secretion signals and
placed under the control of the IPTG inducible T7 promoter in
the expression vector pET23a. The vector derived 66His tag was
not used in lieu of an engineered streptavidin tag, and expression
in each recombinant strain was verified using an anti-streptavidin
antibody (Figure 4). The product of MSMEG_1403 is not the
ortholog of Rv3802, rather it is a homologous protein we purified
from M. smegmatis culture supernatant for its PLA activity [22].
Though not the focus of this manuscript, we include information
on MSMEG_1403 here because it confirms that cutinases have
PLA and TE activity, novel activities for this class of enzymes. In
addition, it demonstrates that a non-orthologous cutinase,
MSMEG_1403, is not inhibited by THL, which is significant
because growth of M. smegmatis in culture also is not inhibited by
THL [23]. Amino acid changes in Rv3802 were made in serines
86, 87 and 175. Each was changed to a glutamic acid. Ser175 is
predicted to be the catalytic serine. Either Ser86 or Ser87 is
predicted to stabilize the oxyanion hole, based on publications
with F. solani cutinase Ser42; these were mutated with the goal of
finding a partially active mutant [24]. Solubility was increased
with use of sarcosyl for membrane disruption. Purity was assessed
to be at least 95% on an SDS polyacrylamide gel stained with a
technique sensitive to 10 ng of protein (Figure 4). Notably,
MSMEG_1403 electrophoreses larger on the gel than Rv3802,
though Rv3802 is predicted to be 32.5 kD and MSMEG_1403
30 kD. Reasons for this are unclear, but it is a consistent finding.
In addition, with MSMEG_1403, dimers and trimers as well as
monomers are often visible.
Figure 1. Mycolic acid synthesis gene cluster in M. tuberculosis H37Rv. Cluster is highly conserved in all actinomycetes.
doi:10.1371/journal.pone.0004281.g001
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M. smegmatis mc
2155 MSMEG_1403 on various
substrates
In order to understand its location in the cell wall pathway,
various substrates and activities were explored. This included
assays for esterase, lipase, phospholipase, thioesterase and
mycolyltransferase activities.
Phospholipids are integral to both host membranes and the
mycobacterial cell wall, and it is known that exogenous
radiolabeled
14C-phospholipids are incorporated into the cell wall
[25,26]. In theory, this is through fatty acid incorporation into the
FAS-II pathway, though complete catabolism may also occur. In
any event, PLA activity is a necessary part of this process, thus we
further investigated the PLA activity of purified Rv3802 and
MSMEG_1403. Of note, we described PLA activity previously,
but on partially purified native protein rather than purified
exogenous protein [22]. To investigate the ability of Rv3802 and
MSMEG_1403 to hydrolyze host and mycobacterial phospholip-
ids, hydrolysis of
14C-radiolabeled phospholipids was assessed by
TLC. Rv3802 and MSMEG_1403 were active in a PLA-type
fashion (hydrolysis to respective lysophospholipid and fatty acid)
on phosphatidylcholine, phosphatidylethanolamine, and phospha-
tidylserine, but not sphingomyelin (Figure 5). The enzymes were
able to hydrolyze both palmitic acid and arachidonic acid
containing phospholipids.
Figure 2. Approximate schematic of proposed mycolic acid synthesis. Fas I enzyme and FasII system elaborate the a and mero chains for
nascent mycolic acids. Carboxylation by AccD4, AccA3 and AccD5 and activation by FadD32 convert these to their respective acyl-S-CoA and acyl-S-
AMP forms. The AT (acyltransferase) domain of Pks13 attaches these via a tioester bond to the phosphopentathiene-modified ACP domains, and
facilitates transfer to the KS (ketosynthase) domain. Via Claisen-type condensation and reduction, the two chains are joined to form a mature mycolic
acid attached via a thioester to Pks13, with loss of CO2. The mature mycolic acid is then hydrolyzed from Pks13 by either the TE1 domain of Pks13, or
an external TE. An external TE2 may function to unclog the Pks13 if it is mis-acylated. The liberated mycolic acid may be transferred to a lipid carrier,
such as Myc-PL, via an unkown MT (mycolyltranferase); this may facilitate its transfer across the plasma membrane. Eventually it is tranferred by
another MT to TMM. TMM is used as a mycolic acid donor for the acceptors of TMM, to form TDM, or AG, to form mAG. Double-boxed enzymes
indicate step involves proteins encoded by genes in the mycolic acid synthesis gene cluster with Rv3802c. Question marks represent activities
encoded by unknown enzymes and a possible role of Rv3802. Adapted from references [7,13,36,44].
doi:10.1371/journal.pone.0004281.g002
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with asterisk over putative catalytic site amino acids.
doi:10.1371/journal.pone.0004281.g003
Figure 4. Products of Rv3802c and MSMEG_1403 expression in E. coli. Left: polyacrylamide gel visualized with Sypro Orange
TM. Right:
immunoblot with streptavidin antibody.
doi:10.1371/journal.pone.0004281.g004
M. tb Rv3802 Inhibited by THL
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nitrophenyl butyrate (NPB) was investigated as a surrogate for
cutinase activity. This is essentially an esterase activity with
colorimetric detection of the nitrophenyl group freed from NPB.
Both enzymes were active esterases, though the turnover rates
were relatively slow (Table 1).
Though Rv3802 may function for hydrolysis only, evaluation of
the mycolic acid synthesis pathway suggests a possible role as a
transferase (Figure 2). Rv3802 and Antigen85A (Rv3804), a known
mycolyltranferase, are both a/b-hydrolase fold enzymes. The acyl
binding pocket of Ag85A functions to transfer the second mycolic
acid onto TMM to from TDM. We therefore investigated
acyltransferase activity of Rv3802 and MSMEG_1403. Various
acyl donors were paired with acceptors in enzyme assays. First, to
investigate transacylation of trehalose (similar to Ag85)
14C-
trehalose was used as the acceptor, and cell wall lipids or crude cell
wall extract (with lipid and protein) were used for donation; no
transacylation was detected except with the positive control,
Ag85C (data not shown). T6P is not currently commercially
available, thus a similar assay was done with the acceptors
mannose-6-phosphate and glycerol-6-phosphate, with no observed
acylated product. These same acceptors were used but the donor
changed to
14C-P-CoA (thioester bond) or
14C-DPPC (ester bond),
and again no acylation occurred, though hydrolysis of the donors
did occur.
14C-P-CoA and
14C-DPPC were again used as donors,
with crude cell wall extract (lipids and proteins, ATP also added)
used for the acceptor; no new acylated products emerged. These
14C-P-CoA and
14C-DPPC assays were repeated with the addition
of crude cell wall extract alone and with cytosolic extract, with the
hope that native donor or acceptor would be present, and again,
no transacylation was observed. Transacylation assays were
repeated several times with different amounts of donor, acceptor
and enzyme, and different amounts of time from 1 to 72 H. The
only result for Rv3802 and MSMEG_1403 in all assays was the
release of fatty acid (not shown).
As a more global cell wall assay, M. smegmatis mc
2 155 cell wall
was radiolabeled with
14C-acetate, and the outer cell wall was
extracted as in methods. This labeled cell wall was assayed with
Rv3802 and MSMEG_1403 protein, and diminution of a labeled
lipid as well as appearance of new lipid with a similar retention
Figure 5. Hydrolysis of various phospholipid substrates by F. solani cutinase (FS), Snake venom PLA (SV), MSMEG_1403 and
Rv3802, demonstrating hydrolysis of all except SM. Thin layer chromatography using
14C-labeled DPPC=dipalmitoyl phosphatidylcholine
labeled on both fatty acids (FA), AAPC=phosphatidylcholine with
14C-arachidonic acid on the sn-2, SM=sphingomyelin
14C-labeled on headgroup,
PE=phosphatidylethanolamine
14C-labeled on sn-2 FA, PS=phosphatidylserine
14C-labeled on headgroup. Inset is equivalent aqueous phase of
phosphatidylserine assay.
doi:10.1371/journal.pone.0004281.g005
Table 1. Kinetics of Rv3802 and Rv3802 S87DE mutant.
Enzyme and Substrate assayed Km, mM Vmax Moles[S] min
21 mg
21 Kcat sec
21 Specificity constant M
21 sec
21
Rv3802 23.52+/23.78 1.62+/20.0861028 8.81+/20.3161023 0.37+/20.01
NPB
Rv3802 12.91+/22.53 8.76+/20.5561029 4.77+/20.2861023 0.37+/20.02
S87DE
NPB
Rv3802 0.017+/20.003 1.35+/20.0461027 7.33+/20.6261022 37.00+/211.08
Palmitoyl-S-CoA
Rv3802 2.28+/21.06 1.11+/20.2561027 8.45+/22.5361022 37.00+/211.08
Decanoyl-S-CoA
Rv3802 S86DE and S175DE are inactive in both assays, as is snake venom PLA2. NPB substrate represents an ester bond, while acyl-CoA substrates represent thioester
bonds.
doi:10.1371/journal.pone.0004281.t001
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14C-palmitic acid resulted. Mass spectrometry
of the apparent substrate revealed it as phosphatidylinositol
mannoside 2 (PIM2); this was purified by normal phase
chromatography on a silica column, and hydrolysis by Rv3802
and MSMEG_1403 confirmed (Figure 6). Based on Rf in this
solvent, the PIM hydrolysis product is consistent with a fatty acid,
including tuberculostearic acid[27]. This result was not surprising
given that we have demonstrated that these enzymes possess PLA
activity.
We investigated the thioesterase activity of these enzymes
because of the possibility that Rv3802 and its orthologs hydrolyze
the thioester bond of nascent mycolic acids on Pks13 as the
terminal event in synthesis or, alternatively, that the Rv3802c gene
product could be a ‘‘proof reading’’ thioesterase. This assay uses
acyl-CoA as the thioester substrate, with colorimetric detection of
TNB
22 formed when DTNB reacts with the hydrolyzed product
HS-CoA[28]. Both M. tuberculosis Rv3802 and M. smegmatis
MSMEG_1403 protein were active as thioesterases (Table 1).
For the kinetic analysis of Rv3802, the time-dependent
hydrolysis of palmitoyl CoA (P-CoA) and decanoyl CoA (D-
CoA) was measured for thioesterase activity, and of NPB for
esterase activity (see Table 1). These kinetic values are similar to
those obtained with other thioesterases. While Rv3802 appears to
favor thioester bonds over ester bonds considering the kinetic
values, the difference in acyl chain length may account for this, as
Rv3802 has a higher affinity for hexadecanoyl than decanoyl
thioesters. A comparison between similarly acylated thioesters and
esters would be of interest, but we are limited by available
substrates and solubility of compounds, as the nitrophenyl esters
are less soluble in aqueous solvents than CoA thioesters, and thus
one would end up comparing a soluble substrate to a micellar
substrate, which may influence results [29]. Rv3802 was not active
on acetyl-CoA. The Rv3802 mutants of S175DE and S86DE were
essentially inactive, while the S87DE mutant is partially active in
both assays (Table 1). Snake venom PLA2 was not active in either
the colorimetric esterase or thioesterase assays (data not shown).
Inhibition of M. tuberculosis Rv3802 and non-inhibition of
M. smegmatis mc
2155 MSMEG_1403 with THL
THL is reported to inhibit the thioesterase domain of human
FAS, thus we investigated the abilityof THL to inhibit M. tuberculosis
Rv3802. Inhibitionof PLAactivity is demonstrated inFigure 7. The
kinetics of inhibition were performed using the thioesterase assay.
Complete inhibitionwas seen at THL concentrationof3.125 mM, a
molar excess of 6.7:1 inhibitor to enzyme. The apparent Ki and
IC50 for THL against Rv3802 are 5 and 250 nm, respectively,
which are lower than against human FASTE, for which the
apparent Ki and IC50 are reported at 100 nm and 1.3560.34 mM,
respectively [30]. It is significantly better than the 200:1 molar
excess needed for partial inhibition reported against the only
reported mycobacterial target of THL, Rv0183[30–32]. Interest-
ingly, THL did not inhibit MSMEG_1403 up to THL concentra-
tions of 25 mM, a 500 M excess.
Discussion
In this report we described the heterologous expression,
purification and enzymatic characterization of an annotated
cutinase, Rv3802, from a mammalian pathogen. Though the
proteins encoded by M. tuberculosis cutinases, including Rv3802,
have been immunologically characterized, their function in
organisms that do not encounter cutin has not been elucidated
[33]. We previously attributed mycobacterial PLA activity to the
Figure 6. Hydrolysis of PIM purified on a waters column. Dot
over O represents origin. Lane 1 is purified PIM control. Lanes 3 and 4
contain PIM plus Rv3802 and MSMEG_1403, respectively.
doi:10.1371/journal.pone.0004281.g006
Figure 7. TLC demonstrating thioesterase activity of Rv3802 on
14C-labeled P-CoA and its inhibition by THL, structure above
(adapted from DrugBank, http://www.drugbank.ca/drugs/DB01083). Lanes: 1)
14C-P-CoA alone, 2–8) serially dilutions decreasing the
amount of THL from 12.5–0 mM THL with 3.0 mg of Rv3802. Origin is indicated with an O, start substrate indicated with P-CoA, hydrolysis product
indicated with FA (fatty acid).
doi:10.1371/journal.pone.0004281.g007
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activity. Logical potential uses for these activities by a mammalian
pathogen include host lipid hydrolysis for carbon scavenging, or
mycobacterial cell wall construction/remodeling. As there are
seven annotated cutinases in M. tuberculosis, it may be they serve a
variety of functions. The function of Rv3802c and its orthologs is
suggested by its location in a gene cluster for mycolic acid
synthesis. In addition, the importance of Rv3802c is supported by
its putative essentiality, its ubiquitous presence in actinomycetes,
and its unique conservation in the minimal genome of M. leprae.
To date, all of the genes surrounding Rv3802c are demonstrated to
serve vital functions in mycolic acid synthesis. This genetic data
implying a role in mycolic acid synthesis is further supported by
Rv3802’s: (i) membership in the a/b-hydrolase fold family with
known PLAs, mycolyltransferases and thioesterases; (ii) possession
of thioesterase activity; and (iii) enzymatic inhibition by a known
mycolic acid synthesis inhibitor, THL.
The compound THL is sold over the counter as the weight loss
agent Alli
TM. It inhibits pancreatic lipase so that long chain fatty
acids cannot be absorbed. During activity based screening, THL
was noted to be a selective inhibitor of the TE domain on human
FAS [30]. FAS is a modular protein like Pks13. FAS has little effect
on normal cells because they take up dietary lipids but, in tumor
cells, FAS is upregulated and contributes to angiogenesis; thus
THL is currently a lead compound in the development of
anticancer drugs [28,34]. This development is focusing on creating
more absorbable and specific forms[30,35]. The published
apparent Ki and IC50 for THL against human FASTE are
100 nm and 1.3560.34 mM, respectively[36]. THL has been
demonstrated to inhibit M. tuberculosis growth at ,30 mg/mL,
decreasing the production of mycolic acids with concomitant
defects in the cell wall, though the target(s) were undefined [23].
Possible targets of THL, including the diacylglycerol acyltransfer-
ase Rv3130 and the FAS-I and II pathways were investigated, but
none were identified as a target[23]. A monoglyceride lipase,
Rv0183, was later identified as a possible target, but a 200:1 molar
excess of inhibitor to enzyme was needed to see an effect[32]. Based
on our knowledge that Rv3802 is an a/b-hydrolase fold with TE
activity, and the structure of THL, we investigated the ability of
THL to inhibit recombinant Rv3802 and found it to inhibit at
nanomolar concentrations, as described. The mechanism of
inhibition is assumed to be similar to the mechanism of human
FASTE inhibition. For human FASTE, THL is demonstrated to
inhibit competitively, with the palmitic core of THL fitting into the
hydrophobic substrate binding pocket and the hexanoyl tail packing
against the catalytic histidine, significantly delaying hydrolysis
(Figure 7) [31,34]. Eventually it is hydrolyzed, thus inhibition is
reversible. The inhibition of an enzyme whose gene is located in the
mycolic acid synthesis gene cluster, together with previously
published observations that THL affects the cell wall and decreases
mycolic acids, supports a cause and effect relationship between THL
and Rv3802. Although we demonstrated that THL inhibits Rv3802
in assays, this does not confirm that Rv3802 is the primary target of
THL in culture. It is likely that THL inhibits other enzymes. In any
case, the knowledge that THL inhibits Rv3802 at least gives a
framework for exploring inhibition of Rv3802 and other THL
targets further in M. tuberculosis.
Though further investigation will be required to pinpoint the
exact function of Rv3802, examination of the mycolic acid
synthetic pathway suggests a role as a Pks associated thioesterase
or as a mycolyltransferase. Though we could not demonstrate
mycolyltransferase activity, our data is limited by the need to use
surrogate substrates and acceptors, thus this remains a distinct
possibility. There are multiple unknown mycolyltransferases
required in the pathway, and similarities between the known
mycolyltranferase Ag85 proteins and Rv3802 are hard to ignore.
However, the unusual ability to hydrolyze thioesters strongly
suggests some type of interaction with nascent mycolic acids while
docked via thioester bonds on Pks13.
Interaction with Pks13 could be in the form of an exogenous
type 1 thioesterase, (TE1) or as an exogenous type 2 thiosterase
(TE2) [37]. Type I polyketide synthases (PKSs) are modular,
‘‘assembly line’’-like enzymes responsible for the steps in the
biosynthesis of polyketides and mycolic acids [38]. Pks13 in M.
tuberculosis has all the necessary modules to produce a mature
mycolic acid: one acyltranferase domain for loading and transfer
of selected acyl chains to the phosphopentatheine (PP) binding
motif of the acyl-S-carrier protein (ACP) domain; two ACPs for
thioester binding, via a PP, of the meroacyl chain from FadD32
and the 2 carboxyl-C26 chain from AccD4, AccA3 and AccD5; a
ketoacyl synthase domain for Claisen-type condensation; and one
TE1 domain for chain termination and hydrolysis. The reduction
event to form the mature mycolic acid may be catalyzed by more
than one protein, but to date CmrA has been identified[8]. The
mature mycolic acid can then be exported and transferred to the
mycolate containing components of the mycobacterial cell wall,
via unknown mycolyltranferases. However, it has been proposed
that the TE1 on the C terminal domain of Pks13 does not liberate
the mature mycolic acid because the presence of free mycolic acid
would be unwieldy for the cell [7]. A solution to this problem is to
have an external TE1 with mycolyltranferase activity. In theory,
Rv3802 could fill this role, though admittedly we find no clear
precedent for this in the literature.
An alternative role for this protein is that of the precedented
TE2. TE2s are well described in association with Pks and NRPS
modules in bacteria, fungi and plants, and serve to proofread the
nascent product on the synthetic module [39]. They are specific
for their corresponding ACP[40,41]. Without a functioning TE2,
erroneous acyl chains on a Pks module clog the machinery,
decreasing product production by up to 90% [38]. If the Pks
product is a secondary metabolite, this diminution is not crucial.
However, in the case of mycolic acids, this diminution could
render the bacterium non-viable.
A role as a TE1 or as a TE2 are both consistent with the
putative essentiality of Rv3802c and the decrease in mycolic acids
observed with THL. Significant amino acid similarity between
TE1s or TE2s and cutinases is not found by search programs, yet
the TE1s, TE2s and cutinases are all a/b-hydrolase fold enzymes
with SDH motifs. In Rv3802, which otherwise shares little amino
acid similarity to the cutinases (0–40%), the spacing of the SDH is
more similar to thioesterases than to cutinases; structure prediction
models find structural similarity of Rv3802 with known cutinases
and thioesterases at 100% and 75% precision, respectively
(Figure 8) [42].
Though there are multiple lines of evidence for involvement in
mycolic acid synthesis, a drawback of our studies is that the data is
indirect; further evaluation is underway, but due to complexity will
take some time. The genetic location of Rv3802c and the
thioesterase activity of its gene product are not likely to be
coincidental, and inhibition by THL further supports this
hypothesis. However, an alternative role interacting with host or
mycobacterial lipids by Rv3802 or the other mycobacterial
annotated cutinases is a possibility. These enzymes clearly possess
PLA activity, and are able to hydrolyze the mycobacterial
phospholipid PIM. If indeed there is a phospholipid carrier
involved in mycolic acid synthesis, or if indeed host derived fatty
acids can go directly into the FAS-II pathway, PLA activity may
actually be linked to mycolic acid synthesis [7,10].
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Our studies suggest M. tuberculosis Rv3802, previously annotated
as a cutinase, is involved in mycolic acid synthesis. Activity as
either a mycolyltransferase or a Pks associated thioesterase are
logical roles for Rv3802, and are consistent with its genetic
location, its discovered thioesterase activity, its inhibition by THL,
and the previously published cell wall defects observed with use of
THL as an antimycobacterial compound. However, this evidence
is circumstantial and further direct evidence is needed to support
or refute such a role for Rv3802.
Materials and Methods
Bacterial strains and culture conditions
M. smegmatis mc
2 155 (ATCC 700084) was purchased from
ATCC. M. smegmatis was grown at 37uC in Luria-Bertani (LB)
broth with 0.05% Tween80H. Escherichia coli strains DH5a and
Rosetta 2 (DE3)pLysS (Merck) were grown at 37uC in LB broth.
Antibiotics (Sigma) were added to media at the following
concentrations: Ampicillan 100 mg/mL, Kanamycin 25–50 mg/
mL, Chloramphenicol 34 mg/mL.
Cloning Procedures
Standard PCR strategies with Taq DNA polymerase (Invitro-
gen) were used to amplify the M. tuberculosis Rv3802c and M.
smegmatis M_SMEG 1403 genes. PCR amplifications consisted of
one cycle of denaturation (95uC, 10 min), followed by 30 cycles of
amplification that included denaturation (95uC, 1 min), annealing
(65uC, 1 min), and primer extension (72uC, 1 min). The primers
used were as follows: 59-catatgggatgccctgacctgcactggatcggc-39 and
59-gagctctcatttttcgaactgcgggtggctccaagcgctgcctaacgtcggagcg-
ggctc-39 for M. smegmatis MSMEG_1403 gene, and 59-catatgggc-
gaatcgccgcccagcgcgg-39 and 59-gagctctcatttttcgaactgcgggtgg-
ctccaagcgctcctatgtttggggtggggcgc-39 for M. tuberculosis Rv3802c
gene. Primers were designed to provide PCR amplified fragments
containing a C-terminal streptavidin tag (bold) and flanking NdeI
and SacI restriction sites (underline). Fragments were cloned into
PCR2.1 (Invitrogen) and colonies for subsequent cloning were
confirmed with sequencing. Correct clones were sub cloned into
pET23a (Novagen). This vector was used as a template to make
three mutants in M. tuberculosis Rv3802c via the QuickChangeH II
method (Stratagene, 2005245, per manufacturer protocol).
Primers used were 59-ctgatcgggtttgagcagggcgcggtg-39 and 59-cacc-
gcgccctgctcaaacccgatcag-39 for Rv3802 DS175E, 59-ggaacctgg-
gaggaatcgccgcagcag-39 and 59-ctgctgcggcgattcctcccaggttcc-39 for
Rv3802 DS86E, and 59-cctgggagtcagagccgcagcagaaccc-39 and 59-
gggttctcgtgcggctctgactcccagg-39 for Rv3802 DS87E.
Expression and purification of recombinant proteins M.
tuberculosis Rv3802, its mutants, and M. smegmatis
mc
2155 MSMEG_1403 in E. coli
The constructs in pET23a described above were transformed into
electrocompetent Rosetta 2 (DE3)pLysS for expression using the T7
promoter. Cultures were induced with 1 mM isopropyl-B-D-
thiogalactopyranoside (IPTG) for 3 H at 37uC. Following induction,
cell pellets were collected and re-suspended in 5 mL Strep-tactin lysis
buffer (50 mM NaH2PO4 and 300 mM NaCl, pH 8.0 with 1 mg/
mL lysozyme and 5 mg/mL DNase I) per 200 mL original induction
c u l t u r e ,a n ds t o r e da t220uC overnight. Thawed resuspensions with
2% (w/v) n-lauryl sarcosine was mixed for $60 min at room
temperature until lysate was clear of large clumps. After centrifuga-
tion, target protein was purified from lysate using strep-tactin
Superflow resin (IBA, Germany) per company protocol. Protein
concentration and absorbance spectra of these aliquots were
e v a l u a t e da t2 8 0n mo naN a n o d r o p
TM system. All eluted protein
samples, if not used immediately, were stored at 270uC. Selected
fractions were also analyzed with sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis and either stained or immunoblotted using
an anti-streptavidin tag antibody (IBA) at 1:1500 and secondary
horseradish peroxidase goat anti-mouse (1:20 K), and visualized with
chemiluminescence. Fractions were estimated to be at least 95% pure
using SYPRO orange staining (molecular probes S5692, per
protocol, sensitive to 5 ng of protein) with phosphoimager detection.
Whole Cell Radiolabeling Experiments
For radiolabeling of whole M. smegmatis mc
2155 cells with
14C,
M. smegmatis was grown in LB medium supplemented with 0.05%
TweenH 80 and, when in log phase,
14C-acetate (ARC 0173B) was
added at 1 mCi/mL and cells were grown for four additional H.
Cells were then pelleted, and extracted with 30 mL
CHCl3:CH3OH (1:2, v/v) per gram of wet cells. Debris was
again pelleted, extract removed, and re-extracted with the same
volume of CHCl3:CH3OH (2:1, v/v). Extracts were combined and
Folch washed. Organic layer was aliquoted and dried down in pre-
weighed vials. For mass spectrometry, a parallel experiment was
done without
14C-acetate. To isolate PIM species, 400 mg was
resuspended in CHCl3 and applied to a silica column (Waters,
WAT023537) and eluted with CHCl3:CH3OH, in percentages (v/
v) of 90:10, 80:20, 70:30, 60:40 and 50:50. PIMs were collected
from the 60:40 and 50:50 fractions.
Mass spectrometry of extracted cell wall lipids
Cell wall lipids were isolated as above. Lipids were applied to
Silica gel 60A ˚ plates (Whatman, 4807-425), and developed in
Figure 8. Structure prediction of Rv3802 using the Phyre server (http://www.sbg.bio.ic.ac.uk/,phyre/, Bennett-Lovsey et al, 2008).
Model on left predicts a cutinase with 100% precision; modeling on right predicts a thioesterase with 70% precision. Black arrow represents location
of catalytic serine 175.
doi:10.1371/journal.pone.0004281.g008
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lipid were scraped from the plate into columns made from Pasteur
pipettes that were fitted with 0.2 mm, Type FG Fluoropore
membrane filters (Millipore). The silica gel was rinsed with 1 mL
of 2:1 i-C3H7OH/H2O and lipid species were eluted with 1 mL of
2:1 (v/v) CHCl3/CH3OH. Samples were evaporated to dryness,
re-dissolved in 2 mL of the same solvent and 0.5 mL was deposited
onto a sample stage that had been pre-spotted with 2,5-
dihydroxybenzoic acid (DHB) for analysis by matrix assisted laser
desorption ionization (MALDI) mass spectrometry. Mass spectra
using a laser wavelength of 337 nm were obtained from m/z 100
to 2400 using a QSTAR XL tandem mass spectrometer (Applied
Biosystems/MDS Sciex, Thornhill, Ontario, Canada). The mass
analyzer configuration of this instrument, mass-resolving quadru-
pole – collision quadrupole – orthogonal time-of-flight (Q-q-
oTOF), allowed both full and collision induced dissociation (CID)
spectra to be obtained. PIM species were identified based on
molecular weight, interpretation of CID spectra, and comparison
of spectra with data found in the literature [43,44].
Cell-free Assay on M. smegmatis crude cell wall and
purified PIM components
Aliquots of
14C-radiolabeled cell wall or purified PIM were
resuspended at 2 mg/mL in 50 mM Bis-tris, pH 7, with 0.25%
TritonH-X 100. 50 mL of this was added to 10–50 mg of enzyme in
50 mL, for a total reaction volume of 100 mL. After 2–5 H, the
reaction was quenched with 200 mL of CHCl3:CH3OH:HCl
(50:50:0.3, v/v/v), and the organic phase removed and plated
under a nitrogen stream on Silica gel 60A ˚ plates (Whatman, 4807-
425). Plates were developed in CHCl3:CH3OH:NH4OH (80:20:2,
v/v/v) and visualized with a phosphoimager (radiolabel) and/or
cupric sulfate or Dittmer-Lester stains (radiolabeled and unla-
beled). For mass spectrometric analysis, a parallel experiment was
performed without radiolabel and lipid species were recovered as
described above.
Determination of activity of recombinant proteins M.
tuberculosis Rv3802, its mutants, and M. smegmatis
mc
2155 MSMEG_1403 on other phospholipid substrates
Control enzymes. 6 units of snake venom PLA2 (Naja
mossambica mossambica, Sigma P-7778) were used per reaction for
a PLA activity control. Lyophilized F. solani cutinase (kind gift from
Unilever Research and Development, Vlaardingen, The
Netherlands) was resuspended at 3 mg/mL in H2O and then
further diluted depending on assay.
Phospholipid assays. Unlabeled dipalmitoyl phosphatidyl-
choline (DPPC) was resuspended at 23 mM in chloroform, and
used as a micellar backbone in all reactions. Radiolabeled phos-
pholipids were as follows: phosphatidylcholine L-a-dipalmitoyl
[dipalmitoyl-1-
14C] (NEC682, 110 mCi/mM), bovine sphingo-
myelin [choline-methyl-
14C] (NEC663, 52 mCi/mM), and phos-
phatidylethanolamine, L-a-palmitoyl-2-arachidonyl [arachidonyl-
1-
14C] (NEC-783, 48 mCi/mM), all from NEN Life Science
Products, and 3-phosphatidyl-[3-
14C]serine 1,2-dioleoyl (CFA757,
54 mCi/mM) from Amersham Biosciences. Cold DPPC with
0.1 mLo f
14C-radiolabeled phospholipid per reaction were dried
down and then resuspended with 50 mL of 50 mM bis-tris pH 7.4
buffer with 0.25% TritonH-X 100 per reaction to make mixed
micelles. This solution was sonicated 30 s63, vortexing in
between. 50 mL of this substrate was then added to 50 mLo f
enzyme solution (10–50 mg), and incubated at 37uC three H. The
reaction was extracted with 100 mL of chloroform/methanol/HCl
(50:50:0.3, v/v/v), vortexed and centrifuged at 13,000 rpms for
two min. The organic phase was then plated on 60 A ˚ silica plates
(Whatman 4807-425) and then developed in CHCl3:CH3OH:H2O
(v/v/v, 14:6:1) solvent. Lipids were visualized with a phosphoimager.
Thioesterase, esterase, and transferase activity of
recombinant of M. tuberculosis Rv3802, its mutants, and
M. smegmatis mc
2155 MSMEG_1403, with and without
the inhibitor THL
Control enzymes included F. solani cutinase, the general esterase
Thermomyces lanuginosus (Sigma L-0777) and M. tuberculosis Ag85C
(Tuberculosis Research Materials and Vaccine Testing, Colorado
State University).
Nitrophenyl ester assays. hydrolysis of NPB (Sigma,
N9876) was used as a surrogate for cutinase activity. Though
both M. smegmatis MSMEG_1403 and M. tuberculosis Rv3802 were
active in this assay, kinetics was done with only Rv3802. For
kinetic calculations, each 200 mL reaction contained 0.01 mg of
enzyme (1.53 mM), the path length was 0.8 cm and the extinction
coefficient was 15250 M
21 cm
21[45]. The NPB 5.69 M stock was
diluted in 50 mM bis-tris/5% glycerol (pH 7.0) for use in the
assays. The final substrate concentration ranged from 1.56 mM–
200 mM. Assays were done in 96 well plates, in triplicate, at 37uC
for four H, with proper controls. There were three replicate
experiments. Absorbance was read by a plate spectrophotometer
at 415 nm at various time points. Prizm 5.0 software were used to
determine Km and Vmax and these were used to determine the kcat
and specificity constant for the esterase activity of Rv3802 and
mutants. Up to 10 units of snake venom PLA was also tested and
was inactive.
Thioesterase activity assays. hydrolysis of P-CoA (Avanti,
870716) and D-CoA, (Sigma, D5269) were used to measure
thioesterase activity. When the thioester bond is hydrolyzed, the
free sulfur on CoA is attacked by 5,59-dithio-bis(2-nitrobenzoic
acid) (DTNB), which releases a measurable nitrophenyl group, 5-
thio-2-nitrobenzoate (TNB
22). For kinetic calculations, each
200 mL reaction contained 3 mg of enzyme (461 nm), the path




22 (Sigma). The P-CoA 20 mM stock
was diluted in 50 mM bis-tris (pH 7.0) for use in the assays. The
DTNB 40 mM stock was diluted in EtOH to give a molar
equivalent amount of DTNB to acyl-CoA for the reaction
(Increasing DTNB relative to P-CoA did not increase reaction
rate, and DTNB did not react with enzyme alone). The final P-
CoA concentration ranged from 4.875 mM – 2.5 mM, and the
final D-CoA concentration ranged from 0.078 to 5.0 mM. Assays
were done in 96 well plates, in triplicate, at 37uC for three H, with
proper controls. There were four replicate experiments.
Absorbance was read by a plate spectrophotometer at 415 nm
at various time points. Prizm 5.0 software was used to determine
Km and Vmax and these were used to determine the kcat and
specificity constant for the thioesterase activity of Rv3802. For
radiolabel
14C-P-CoA assays, protocol was followed as in
14C-
phospholipids assays above.
THL inhibition assays. four concentrations of THL (Sigma,
04139) were selected in order to determine Ki and nature of
inhibition of Rv3802, based on pilot experiments: 1.56 mM,
0.78 mM, 0.39 mM, and 0.195 mM. 100% inhibition of activity
was seen at 3 mM final concentration. Inhibition assays were
performed identically to the thioesterase assays without inhibitor
described previously, except that after the addition of THL and
before the addition of P-CoA, the assay was incubated at 37uC for
30 min [39]. The Reaction was run for 1–2 H, in duplicate, and
four replicates were performed. Changes in Km and Vmax
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5.0 software, as were apparent Ki and IC50 values. For inhibition
of M. smegmatis MSMEG_1403, each 200 mL reaction contained
0.3 mg (0.495 mM). THL concentration was increased to a
maximum of 25 mM (a molar excess compared to enzyme of
505) in an attempt to detect inhibition.
Transferase assays. donors and recipients were paired for
various transferase assays to assess whether the purified enzymes
could hydrolyze a known substrate and transfer it to an acceptor.
Assays included 10–50 mg of either Rv3802 or MSMEG_1403
protein, and were incubated for 1–72 H. Pairings included: 1)
14C-
trehalose (0.25 mCi) with crude cell wall lipids (50 mg) from M.
tuberculosis;2 )
14C-P-CoA (0.25 mCi) as donor with mannose-6-
phosphate (1–10 mM) or glycerol-6-phosphate (1 mM) as acceptor
with crude cell wall extract (proteins and lipids for unknown
cofactors or other acceptors, total 0.1 to 1 mg, made per
previously described protocol[27]; 3) same as two with addition
of crude cytosolic extract, 4) same as in two and three with
addition of
14C-trehalose (0.25 mCi); 5) same as two and three with
14C-DPPC instead of
14C-P-CoA. As a positive control for the
mycolyltranferase assays using
14C-trehalose as an acceptor,
Ag85C was used at 10–50 mg per assay.
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